Aescin Encyclopedia — Scientific Background

What Is Aescin?

Aescin (CAS 6805-41-0 for the aescin mixture; 20977-05-3 for sodium aescinate), also known as escin, is a triterpene saponin complex extracted from the dried seeds of Aesculus hippocastanum L., commonly known as horse chestnut. It is a mixture of closely related triterpene saponins, primarily consisting of escin Ia, Ib, IIa, and IIb, with the β-aescin fraction representing the most pharmacologically active component. The molecular formula of the aescin complex is C₅₅H₈₆O₂₄ with a molecular weight of approximately 1131.26 g/mol. The monosodium salt (sodium aescinate) has the molecular formula C₅₄H₈₄NaO₂₃ and a molecular weight of 1124.2 g/mol.

Botanical Source and Standardization

Aescin is extracted from the dried ripe seeds of Aesculus hippocastanum L., the horse chestnut tree, a large deciduous tree native to the Balkan Peninsula and widely cultivated throughout temperate regions. The seeds contain 3–10% aescin, with the highest concentration in the seed kernel. Commercial horse chestnut seed extract is standardized to contain a defined content between 16% and 28% triterpene glycosides, calculated as aescin, and is prepared as an aqueous-alcohol extract (40–80% V/V ethanol). The standardised extract is available in various pharmaceutical forms, including tablets, capsules, and topical gels and creams. For topical preparations, 1 g of cream typically contains 50 mg of dry extract standardized to 10 mg aescin.

Mechanisms of Action

Anti-Edematous Activity — Capillary Permeability and Venous Tone

Aescin‘s primary therapeutic mechanism involves the inhibition of exudation by reducing the extravasation of fluid into the tissue and accelerating the subsidence of oedema. The mode of action is based on changes in the permeability of the affected capillary walls. In addition, aescin raises capillary resistance, inhibits inflammatory processes, and improves microcirculation. Aescin improves the entry of ions into channels, thus raising venous tension in both in vitro and in vivo conditions.

Anti-Inflammatory Mechanisms — PGF₂α Release and 5-HT Antagonism

The anti-inflammatory and anti-oedematous effects of aescin are mediated through multiple pathways. Aescin at concentrations of 5–10 mg/mL releases PGF₂α from veins, and this effect is abolished by non-steroidal anti-inflammatory drugs, indicating that the effect is dependent on PGF₂α in the venous tissue. Furthermore, aescin pre-treatment reduces IL-6 release from LPS-activated vascular endothelium. Other mechanisms include antagonism to 5-HT and histamine, and reduced catabolism of tissue mucopolysaccharides.

Venotonic Activity — Ion Channel Modulation

Aescin‘s venotonic properties are related to its molecular mechanism of allowing improved entry of ions into channels, thus raising venous tension in both in vitro and in vivo conditions. This mechanism directly addresses the venous stasis and impaired venous return that characterize chronic venous insufficiency.

The Bioavailability Challenge

Despite its therapeutic efficacy, native aescin presents significant bioavailability challenges. Following oral administration, only 13–16% of an aescin dose is absorbed (non-volatile radioactivity), with peak plasma concentrations achieved approximately 4 hours after administration. Aescin undergoes significant first-pass metabolism, resulting in a plasma bioavailability of only 1.5%. Sodium aescinate is often used for intravenous injection due to these limitations, but its clinical application is further limited by strong irritation, short half-life, and low bioavailability.

These limitations have driven the development of advanced delivery systems, including liposomes, solid lipid nanoparticles, and polymeric nanoparticles. Among these, liposomal encapsulation has emerged as one of the most effective strategies for enhancing aescin bioavailability, safety, and therapeutic efficacy.

Liposomal Aescin

Liposomal encapsulation of aescin provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the aescin molecule, forming a nanoscale vesicle that enhances stability, safety, and cellular uptake. This delivery system:

• Achieves a mean particle size of 117.33 ± 0.95 nm with PDI of 0.140 ± 0.017 and zeta potential of −30.34 ± 0.23 mV

• Demonstrates cumulative release exceeding 80% at 12 hours

• Exhibits 2.12-fold higher LD50 compared to commercial sodium aescinate injection

• Does not induce hemolysis at 37°C and produces significantly milder venous irritation

• Remains stable in simulated gastric fluid, simulated intestinal fluid, phosphate buffer, and physiological saline

The SA-Lip-I formulation prepared by lyophilization with phospholipid demonstrated better efficacy than the unencapsulated SA-I, with a significant difference. The modified SA-Lip-I is a promising preparation that can reduce irritation and toxic side effects, improve the treatment effect to a certain extent, and greatly alleviate patient pain during treatment, achieving the optimal curative effect.

Clinical Evidence

Post-Traumatic and Post-Operative Edema — Randomized Controlled Trials

A double-blind, parallel-group, 3-arm clinical study enrolled 300 patients with postoperative or post-traumatic soft tissue swelling (contusion, sprain, or fracture traumas). Patients were treated for 14 days with oral escin (20 mg three times daily), placebo, or a fibrinolytic control drug (serratiopeptidase 5 mg three times daily). There was a reduction in edema (slight improvement or better) in 82.3% of patients in the oral escin group compared with 75% in the fibrinolytic control group and 72.4% in the placebo group (p<0.05 for escin vs. placebo by day 3). Escin also scored significantly better in subjective evaluation criteria at the end of the 14-day treatment. The number of adverse events in the three groups was 4 (4.1%), 7 (7.1%), and 8 (8.1%), respectively.

A placebo-controlled, parallel-group, 4-arm study was conducted in 100 orthopedic patients (50 with post-plastering edema and 50 with reactive post-traumatic edema). In each group, 40 patients received oral escin (2×20 mg three times daily) and 10 were treated with placebo. Limb circumference, plethysmography, and the presence or absence of spontaneous pain were evaluated. Treatment with escin improved post-plastering edema in 92% of patients and post-traumatic edema in 95% of patients, with the majority of the improvement occurring in the first 3 weeks of treatment. The mean difference in water volume change after 4 weeks of treatment was −680 mL post-plaster and −1090 mL post-trauma with escin, and −230 mL post-plaster and −330 mL post-trauma with placebo.

Chronic Venous Insufficiency — Clinical Evidence

Standardized horse chestnut seed extract (aescin) has been shown to significantly reduce symptoms of chronic venous insufficiency. In a controlled trial, aescin was shown to be as effective as compression therapy as an alternative to medical treatment for CVI. A Cochrane review systematically analyzed 17 clinical studies of horse chestnut seed extract for chronic venous insufficiency, concluding that it significantly reduces symptoms. The efficacy of oral escin administration in patients with CVI was evaluated in a double-blind, randomized clinical study in 80 patients.

Safety and Regulatory

Aescin has an excellent tolerability profile in the clinic, indicating that this treatment is of definite clinical benefit in patients with clinical conditions resulting in CVI, haemorrhoids, or peripheral oedema formation. In the post-traumatic edema trials, adverse event rates were 4.1% for escin, compared with 8.1% for placebo.

Regulatory status varies by region:

• European Union — The European Medicines Agency (EMA) Committee on Herbal Medicinal Products (HMPC) has published a European Union herbal monograph on Aesculus hippocastanum L., semen, establishing well-established and traditional use indications for horse chestnut seed preparations. The monograph covers preparations standardized on aescin and recommends daily oral doses corresponding to 100 mg of aescin for well-established use in chronic venous insufficiency.

• United States — Horse chestnut seed extract is regulated as a dietary supplement ingredient. The standardised extract is commercialized in various forms including capsules, tablets, and topical preparations.

• Japan — Horse chestnut extract is classified as a “food with function claims” ingredient, requiring clinical evidence for specific health claims. Products are available with rigorous documentation including heavy metal testing below 10 ppm, microbial limits, and stability data.

• Global Standards — Aescin is monographed in the European Pharmacopoeia and other pharmacopoeias. The product is available with Halal certification, and the manufacturing process ensures compliance with international quality standards.

Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

1799$/KG

1399$/KG